利用sFlt-1/PlGF比值预测妊娠期糖尿病患者的子痫前期
该回顾性分析纳入澳大利亚墨尔本皇家妇女医院2016年9月至2022年9月间的1416例sFlt-1/PlGF比值结果,比较伴或不伴妊娠期糖尿病(GDM)的子痫前期(PE)患者。在分娩前0-7天和8-14天两个时间段内,PE+无GDM组与PE+GDM组的AUC、特异性、敏感性、阳性预测值及阴性预测值均无显著差异。结论认为GDM虽可能改变sFlt-1/PlGF比值,但该比值预测PE发病的临床效用依然保留。
要点
- 在分娩前0-7天,PE+无GDM组与PE+GDM组的AUC、敏感性、NPV等指标均无显著差异。
- PE+GDM组在0-7天分类中AUC为0.87,敏感性89.4%,NPV为94.8%。
- GDM可能影响sFlt-1/PlGF比值水平,但不影响其预测PE的临床效用。
核心结论
- 研究结果表明,尽管GDM可能导致sFlt-1/PlGF比值发生变化,但该比值检测在预测PE发病方面仍保留其临床效用。
研究设计与样本
- 回顾性分析2016年9月至2022年9月在澳大利亚墨尔本皇家妇女医院获取的sFlt-1/PlGF比值及相关临床结局数据,共分析1416例孕妇的sFlt-1/PlGF比值结果,涵盖伴或不伴GDM、伴或不伴PE的孕妇。
主要发现
- 在分娩前0-7天分类中,PE+无GDM组AUC为0.82(95%CI 0.79-0.87),敏感性85.3%(95%CI 80.8-89.1%),NPV为92.7%(95%CI 90.5-94.5%);PE+GDM组AUC为0.87(95%CI 0.82-0.93),敏感性89.4%(95%CI 76.9-96.5%),NPV为94.8%(95%CI 88.7-97.7%)。
- 在0-7天和8-14天两个分类中,PE+无GDM组与PE+GDM组之间的AUC、特异性、敏感性、阳性预测值和阴性预测值均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The soluble Fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio blood test can aid the prediction of preeclampsia (PE) in advance of a clinical diagnosis. Gestational diabetes mellitus (GDM) predisposes to PE, but may influence levels of these biomarkers independently of PE. OBJECTIVE: To determine whether the sFlt-1/PlGF ratio retains its clinical utility to predict PE in patients with GDM. METHODS: Retrospective analysis of sFlt-1/PlGF ratio and associated clinical outcome data acquired between September 2016 and September 2022, at the Royal Women's Hospital, Melbourne, Australia. 1416 sFlt-1/PlGF ratio results from pregnant women with and without GDM, and with and without PE were analysed. The main outcome measures were sFlt-1, PlGF and sFlt-1/PlGF ratio test results in relation to PE and GDM. RESULTS: There were no significant differences in the area under the curve (AUC), specificity, sensitivity, positive predictive value, or negative predictive value (NPV) between the PE + No GDM and PE + GDM groups in both the 0 to 7 and the 8 to 14 days before delivery categories. In the 0- to 7-day category the PE + No GDM group had an AUC of 0.82 (95% CI 0.79-0.87), sensitivity of 85.3% (95% CI 80.8-89.1%) and NPV of 92.7% (95% CI 90.5-94.5%), and the PE + GDM group had an AUC of 0.87 (95% CI 0.82-0.93), sensitivity of 89.4% (95% CI 76.9-96.5%), and NPV of 94.8% (95% CI 88.7-97.7%). CONCLUSION: The results of this investigation indicate that although GDM may lead to changes in the sFlt-1/PlGF ratio, the sFlt-1/PlGF ratio test retains its clinical utility in predicting PE onset.
引用
- Noonan SB, Brennecke SP, Jones GD, et al. Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio. J Clin Endocrinol Metab. 2025. PMID: 39903607. doi:10.1210/clinem/dgaf069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。